OBI-898OBI-898 is a monoclonal antibody targeting SSEA-4, a ganglioside highly expressed in multiple epithelial cancers. OBI-898 has demonstrated high specificity and strong binding ability in preclinical research, making it a development candidate that may greatly enhance the treatment effect in cancer patients with high SSEA-4 expression.
OBI-898 triggers immune response by antibody-dependent cell-mediated cytotoxicity (ADCC). The pathway begins with the Fc region of OBI-898 binding to the Fc receptor of an effector cell. Subsequently, the effector cell may engulf targeted tumor cells or release lysosomes which causes tumor killing. OBI-898 may also trigger complement-dependent cytotoxicity (CDC) which forms a membrane attack complex that causes tumor lysis.
OBI-898 has the potential to be used as a stand-alone treatment or in combination with chemotherapy or radiotherapy to achieve better efficacy and improve patients’ quality of life. As a passive immunotherapy, OBI-898 can also benefit those who are immunocompromised and/or cannot produce antibodies from therapeutic vaccine treatment.
OBI-898 is now in the pre-clinical research stage.